Rapid interrogation of cancer cell of origin through CRISPR editing

Proc Natl Acad Sci U S A. 2021 Aug 10;118(32):e2110344118. doi: 10.1073/pnas.2110344118.

Abstract

The increasing complexity of different cell types revealed by single-cell analysis of tissues presents challenges in efficiently elucidating their functions. Here we show, using prostate as a model tissue, that primary organoids and freshly isolated epithelial cells can be CRISPR edited ex vivo using Cas9-sgRNA (guide RNA) ribotnucleoprotein complex technology, then orthotopically transferred in vivo into immunocompetent or immunodeficient mice to generate cancer models with phenotypes resembling those seen in traditional genetically engineered mouse models. Large intrachromosomal (∼2 Mb) or multigenic deletions can be engineered efficiently without the need for selection, including in isolated subpopulations to address cell-of-origin questions.

Keywords: CRISPR; cancer modeling; editing; organoids.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adaptor Proteins, Signal Transducing / metabolism
  • Animals
  • CRISPR-Associated Protein 9 / genetics
  • Chromosome Deletion*
  • Clustered Regularly Interspaced Short Palindromic Repeats / genetics*
  • Epithelial Cells
  • Gene Editing / methods*
  • Genes, Tumor Suppressor
  • Humans
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Organoids
  • Prostate / cytology*
  • Prostatic Neoplasms / genetics
  • Prostatic Neoplasms / pathology
  • RNA, Guide, CRISPR-Cas Systems
  • Ribonucleoproteins / genetics
  • Transcriptional Regulator ERG / genetics
  • Xenograft Model Antitumor Assays

Substances

  • AKT1S1 protein, human
  • Adaptor Proteins, Signal Transducing
  • ERG protein, human
  • RNA, Guide, CRISPR-Cas Systems
  • Ribonucleoproteins
  • Transcriptional Regulator ERG
  • CRISPR-Associated Protein 9